Merck & Co. (NYSE: $MRK) Sets Up Q125 Earnings Call for April 24

Merck & Co. (NYSE: MRK) will hold its Q1 2025 earnings call on April 24 at 9:00 a.m. ET. Company executives will present financial results and performance updates during the call.
As of April 4th, 2025, MRK closed at $81.47, down $4.92 (5.70%). The stock has declined steadily since peaking at $134 in June 2024.

In Q4 2024, Merck posted global sales of $15.6 billion, a 7% increase from the previous year. Sales growth stood at 9% when excluding foreign exchange effects. Full-year 2024 revenue reached $64.2 billion, a 7% increase over 2023. Human health sales grew 8%, driven mainly by oncology treatments.

KEYTRUDA remained the company’s top product with sales of $7.8 billion in Q4, rising 21%. WINREVAIR generated $200 million in sales, while new vaccine CAPVAXIVE added $50 million. The Animal Health division showed strong momentum, growing 13% year-over-year. Merck’s global reach extended to nearly 500 million people in 2024.

However, GARDASIL vaccine sales dropped 18% in Q4 due to lower demand in China. This led Merck to pause GARDASIL shipments to the region temporarily. Operating expenses for the quarter totaled $7.4 billion. The company reported a gross margin of 80.8%, up by 3.6 percentage points. Earnings per share came in at $1.72.

For 2025, Merck expects revenue between $64.1 billion and $65.6 billion. EPS guidance is set at $8.88 to $9.03, excluding foreign exchange impact. The Medicare Part D redesign could reduce revenue by about $400 million in 2025. This would affect WINREVAIR and other small molecule oncology drugs.

Technical Analysis

MRK stock is currently testing a major support level at $81.A confirmed breakdown at this critical level could push the stock lower. Price momentum and volume suggest a likely continuation of the bearish trend unless support holds. With the bearish pressure in place, the next support level lies at $70.

The weekly chart shows consistent lower highs and lower lows since June 2024. MRK has fallen nearly 65% from its peak of $134.

If the $81 current support holds, a short-term rebound is possible, with an immediate resistance target around $95. Reclaiming this level may signal early signs of a trend reversal. If a strong break at the $81 level is witnessed, the next target remains the $70 support.

The current trend favors sellers. One thing to watch closely is the April 24th, 2025, earnings call as performance updates may provide clarity on near-term price direction.